热门资讯> 正文
Immunome宣布拟议公开募股
2025-12-16 05:07
- Immunome (NASDAQ:IMNM) announced on Monday its plans to commence an underwritten public offering to issue and sell $400M of shares, and the underwriter will have a 30-day option to purchase up to an additional $60M of shares of its common stock.
- Leerink Partners, J.P. Morgan, TD Cowen, Goldman Sachs & Co. LLC, and Guggenheim Securities are acting as joint bookrunning managers for the proposed offering. Wedbush PacGrow and LifeSci Capital are acting as co-lead managers for the proposed offering.
- The proposed offering is being made pursuant to a shelf registration statement filed with the SEC on February 13, 2024, and automatically became effective upon filing.
More on Immunome
- Seeking Alpha’s Quant Rating on Immunome
- Historical earnings data for Immunome
- Financial information for Immunome
推荐文章
美股机会日报 | 美国1月“小非农”不及预期！礼来绩后一度大涨10%，财报强劲超预期
华盛早报 | 辟谣！税收传闻不实；“AI抢饭碗”引抛售潮！纳指跌近1.5%；黄金、白银暴力反弹，华尔街坚定看多
全面甩卖软件股！美股爆发AI恐慌，Anthropic掀起SaaS抛售潮
财报速递 | 超微电脑盘后一度涨逾10%！强劲业绩展望预示AI需求增长
美股机会日报 | 贵金属“大逆转”！金银价再度大涨，机构建议市场回稳再进场；闪迪盘前续涨4%，年内已累涨180%
金银暴跌后“暴力”反弹！华尔街坚定看多：逻辑未破，黄金牛市仍未结束（附相关标的）
抢跑1.5万亿美元造富神话！如何在IPO前投资SpaceX？最全攻略来了
新股申购 | “全球锂电设备龙头”先导智能今起招股！引入欧万达基金等基石投资者
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
